Thank you for your interest in submitting an abstract to the 29th Annual Meeting of the American Association of Psychiatric Pharmacists (AAPP). Posters will be displayed April 20th and 21st and published on aapp.org and in the April or June 2026 issue of the Mental Health Clinician.
The abstract submission center will open in Fall 2025 and submissions will be due January 8, 2026.
The Poster Presenter Handbook provides the most important details for abstract authors. It contains deadlines, submission requirements, poster guidelines, and example abstracts.
Accepted Abstract Categories
Original Research: Abstracts should describe original research in therapeutics, pharmacodynamics, pharmacoeconomics, outcomes, drug utilization, kinetics, genetics and academic pursuits. Abstracts must not have been published in abstract form nor presented as a poster elsewhere before the AAPP 2025 Meeting.
Encore Presentation: Abstracts of papers that have been previously presented and peer reviewed. Submission must include where it was previously presented or the abstract will be disqualified. Encore submissions are not eligible for any of the award categories and should not be submitted for award consideration.
Work in Progress (WIP): Abstracts describing preliminary results or status of ongoing work may be submitted by principal investigators at any stage of their career. Abstracts submitted without results at the time of submission will be considered for this category only.
Innovative Practices: Abstracts describing the development, justification, documentation, and/or delivery of innovative services or activities applicable to psychiatric and neurologic pharmacy. The descriptive abstract should not duplicate any other poster category and should describe the development of innovative services/activities and should provide background/rationale, a description of the innovative service, the impact on patient care/institution and a conclusion.
Therapeutic Case Report: Abstracts describing the various aspects of pharmaceutical care relating to individual psychiatric and/or neurological pharmacy cases. Abstracts should provide a complete patient history including age, gender, time from first diagnosis, social background, and details of, and response to, previous and current treatment(s). Cases should include background, complete patient history, review of literature, and conclusion.